X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4967) 4967
Publication (344) 344
Book Review (109) 109
Newsletter (46) 46
Book Chapter (13) 13
Magazine Article (10) 10
Newspaper Article (8) 8
Conference Proceeding (7) 7
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
etanercept (4609) 4609
humans (3928) 3928
index medicus (2367) 2367
female (2342) 2342
infliximab (2217) 2217
male (2174) 2174
middle aged (1833) 1833
tumor necrosis factor-alpha - antagonists & inhibitors (1777) 1777
rheumatology (1714) 1714
adult (1570) 1570
receptors, tumor necrosis factor - therapeutic use (1446) 1446
immunoglobulin g - therapeutic use (1445) 1445
arthritis, rheumatoid - drug therapy (1412) 1412
adalimumab (1366) 1366
immunoglobulin g - adverse effects (1341) 1341
treatment outcome (1334) 1334
rheumatoid arthritis (1285) 1285
antirheumatic agents - therapeutic use (1254) 1254
antirheumatic agents - adverse effects (1215) 1215
rheumatoid-arthritis (1075) 1075
antibodies, monoclonal - therapeutic use (1010) 1010
aged (965) 965
dermatology (958) 958
therapy (936) 936
psoriasis (930) 930
methotrexate (897) 897
antibodies, monoclonal - adverse effects (874) 874
arthritis (769) 769
psoriasis - drug therapy (753) 753
double-blind (744) 744
efficacy (685) 685
drug therapy (669) 669
care and treatment (615) 615
safety (604) 604
severity of illness index (550) 550
receptors, tumor necrosis factor (524) 524
medicine & public health (515) 515
antibodies, monoclonal, humanized (497) 497
tumor necrosis factor (488) 488
adolescent (470) 470
drug therapy, combination (469) 469
risk factors (463) 463
receptors, tumor necrosis factor - administration & dosage (416) 416
immunoglobulin g - administration & dosage (414) 414
disease (409) 409
patients (398) 398
immunosuppressive agents - therapeutic use (395) 395
tumor necrosis factor-tnf (393) 393
methotrexate - therapeutic use (391) 391
retrospective studies (391) 391
pharmacology & pharmacy (384) 384
rheumatoid factor (383) 383
necrosis-factor-alpha (372) 372
immunology (367) 367
tumor-necrosis-factor (365) 365
child (358) 358
monoclonal antibodies (348) 348
immunosuppressive agents - adverse effects (347) 347
research (343) 343
antirheumatic agents - administration & dosage (337) 337
arthritis, psoriatic - drug therapy (319) 319
antibodies, monoclonal, humanized - therapeutic use (308) 308
time factors (304) 304
dosage and administration (303) 303
trial (298) 298
complications and side effects (297) 297
etanercept - therapeutic use (295) 295
risk (295) 295
clinical trials (294) 294
follow-up studies (294) 294
young adult (292) 292
anti-inflammatory agents, non-steroidal - therapeutic use (289) 289
analysis (285) 285
animals (282) 282
monoclonal-antibody (280) 280
arthritis, juvenile - drug therapy (276) 276
placebo-controlled trial (276) 276
spondylitis, ankylosing - drug therapy (274) 274
health aspects (270) 270
medicine, general & internal (270) 270
internal medicine (269) 269
ankylosing spondylitis (266) 266
inflammation (265) 265
double-blind method (263) 263
tumor necrosis factor-α (262) 262
abridged index medicus (259) 259
tnf-alpha (256) 256
prospective studies (253) 253
antibodies, monoclonal, humanized - adverse effects (236) 236
etanercept - adverse effects (235) 235
children (230) 230
crohns-disease (229) 229
biological products - therapeutic use (228) 228
drug administration schedule (226) 226
antibodies, monoclonal - administration & dosage (224) 224
quality of life (224) 224
studies (223) 223
tnf inhibitors (223) 223
psoriatic arthritis (218) 218
tuberculosis (214) 214
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4768) 4768
French (65) 65
German (63) 63
Japanese (47) 47
Spanish (41) 41
Italian (14) 14
Chinese (7) 7
Danish (5) 5
Swedish (5) 5
Hungarian (4) 4
Portuguese (4) 4
Turkish (3) 3
Dutch (2) 2
Hebrew (2) 2
Korean (2) 2
Norwegian (2) 2
Polish (2) 2
Russian (2) 2
Czech (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Rheumatology (United Kingdom), ISSN 1462-0324, 03/2017, Volume 56, Issue 3, pp. 417 - 425
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 493
BackgroundMethotrexate is usually the first-line disease modifying anti-rheumatic drug (DMARD) for patients with juvenile idiopathic arthritis (JIA), due to... 
Leukopenia | Hypersensitivity | Liver | Rheumatic diseases | Arthritis | Nausea | Patients | Survival | Survival analysis | Side effects | Pain | Etanercept | Vomiting | Remission | Children | Methotrexate | Health risk assessment
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 1640
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 5/2017, Volume 51, Issue 5, pp. 388 - 393
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 01/2013, Volume 108, Issue 1, pp. 99 - 105
OBJECTIVES: The risk of non-Hodgkin's lymphoma (NHL) with tumor necrosis factor alpha (TNF-alpha) inhibitors is unclear, whether related to concomitant... 
RHEUMATOID-ARTHRITIS | INFLAMMATORY-BOWEL-DISEASE | THERAPY | AZATHIOPRINE | RISK | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CANCER | MEDLINE | Azathioprine - therapeutic use | Lymphoma, T-Cell - chemically induced | Certolizumab Pegol | United States | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Polyethylene Glycols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Polyethylene Glycols - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Odds Ratio | United States Food and Drug Administration | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | SEER Program | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Adverse Drug Reaction Reporting Systems | Risk Factors | Spondylitis, Ankylosing - drug therapy | Mercaptopurine - adverse effects | Immunoglobulin G - therapeutic use | Immunoglobulin G - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Immunosuppressive Agents - adverse effects | Aged | Adalimumab | Azathioprine - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Cytokine, ISSN 1043-4666, 01/2018, Volume 101, pp. 56 - 63
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in inflammatory diseases such as rheumatoid arthritis and inflammatory... 
Anti-TNF-α therapy | Inflammatory bowel disease | Tumor necrosis factor-α | Rheumatoid arthritis | RHEUMATOID-ARTHRITIS | COLLAGEN-INDUCED ARTHRITIS | CROHNS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | Anti-TNF-alpha therapy | IMMUNOLOGY | FC-FUSION PROTEINS | CERTOLIZUMAB PEGOL | FACTOR RECEPTOR | CELL BIOLOGY | Tumor necrosis factor-alpha | TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | TRANSMEMBRANE TNF | REGULATORY T-CELLS | Adalimumab - genetics | Antirheumatic Agents - administration & dosage | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Inflammatory Bowel Diseases - immunology | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Infliximab - therapeutic use | Polyethylene Glycols - therapeutic use | Antibodies, Monoclonal, Humanized - genetics | Adalimumab - adverse effects | Certolizumab Pegol - adverse effects | Infliximab - adverse effects | Anti-Inflammatory Agents - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Arthritis, Rheumatoid - drug therapy | Tumor Necrosis Factor-alpha - immunology | Anti-Inflammatory Agents - therapeutic use | Antirheumatic Agents - adverse effects | Anti-Inflammatory Agents - administration & dosage | Certolizumab Pegol - therapeutic use | Certolizumab Pegol - genetics | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Disease Models, Animal | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Infliximab - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin Fab Fragments - genetics | Immunoglobulin G - therapeutic use | Immunologic Factors - genetics | Immunoglobulin G - adverse effects | Antibodies, Monoclonal - genetics | Adalimumab - therapeutic use | Animals | Immunoglobulin G - genetics | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Mice | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer
Journal Article
JEADV : Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 2009, Volume 23, Issue 2, pp. 1 - 70
Journal Article